Combination chemotherapy with cyclophosphamide, vincristine, and prednisolone (CVP) in TNM-classified stage IV mycosis fungoides

U. Tirelli; A. Carbone; A. Veronesi; E. Galligioni; M. G. Trovò; S. Tumolo; E. Grigoletto

Combination chemotherapy with cyclophosphamide, vincristine, and prednisolone (CVP) in TNM-classified stage IV mycosis fungoides

U. Tirelli, A. Carbone, A. Veronesi, E. Galligioni, M. G. Trovò, S. Tumolo, E. Grigoletto

Centro di Riferimento Oncologico

Research output: Contribution to journal › Article

Abstract

Nine patients with stage IV mycosis fungoides (MF), according to TNM classification, were treated with cyclosphosphamide, vincristine, and prednisone (CVP). CVP induced a 66% overall objective response rate and a 44% complete response rate, which is the highest reported in the literature. CVP is an effective regimen in MF and could be employed in combination with total skin or total lymphoid radiotherapy. TNM classification should be used for all patients with MF, because it makes the evaluation and comparison of treatments more reliable.

Original language	English
Pages (from-to)	167-169
Number of pages	3
Journal	Cancer Treatment Reports
Volume	66
Issue number	1
Publication status	Published - 1982

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

Fingerprint Dive into the research topics of 'Combination chemotherapy with cyclophosphamide, vincristine, and prednisolone (CVP) in TNM-classified stage IV mycosis fungoides'. Together they form a unique fingerprint.

Cite this

@article{574c24adfb1648f0bb73a50f7274d1b9,

title = "Combination chemotherapy with cyclophosphamide, vincristine, and prednisolone (CVP) in TNM-classified stage IV mycosis fungoides",

abstract = "Nine patients with stage IV mycosis fungoides (MF), according to TNM classification, were treated with cyclosphosphamide, vincristine, and prednisone (CVP). CVP induced a 66% overall objective response rate and a 44% complete response rate, which is the highest reported in the literature. CVP is an effective regimen in MF and could be employed in combination with total skin or total lymphoid radiotherapy. TNM classification should be used for all patients with MF, because it makes the evaluation and comparison of treatments more reliable.",

author = "U. Tirelli and A. Carbone and A. Veronesi and E. Galligioni and Trov{\`o}, {M. G.} and S. Tumolo and E. Grigoletto",

year = "1982",

language = "English",

volume = "66",

pages = "167--169",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "U.S. National Cancer Institute",

number = "1",

}

TY - JOUR

T1 - Combination chemotherapy with cyclophosphamide, vincristine, and prednisolone (CVP) in TNM-classified stage IV mycosis fungoides

AU - Tirelli, U.

AU - Carbone, A.

AU - Veronesi, A.

AU - Galligioni, E.

AU - Trovò, M. G.

AU - Tumolo, S.

AU - Grigoletto, E.

PY - 1982

Y1 - 1982

N2 - Nine patients with stage IV mycosis fungoides (MF), according to TNM classification, were treated with cyclosphosphamide, vincristine, and prednisone (CVP). CVP induced a 66% overall objective response rate and a 44% complete response rate, which is the highest reported in the literature. CVP is an effective regimen in MF and could be employed in combination with total skin or total lymphoid radiotherapy. TNM classification should be used for all patients with MF, because it makes the evaluation and comparison of treatments more reliable.

AB - Nine patients with stage IV mycosis fungoides (MF), according to TNM classification, were treated with cyclosphosphamide, vincristine, and prednisone (CVP). CVP induced a 66% overall objective response rate and a 44% complete response rate, which is the highest reported in the literature. CVP is an effective regimen in MF and could be employed in combination with total skin or total lymphoid radiotherapy. TNM classification should be used for all patients with MF, because it makes the evaluation and comparison of treatments more reliable.

UR - http://www.scopus.com/inward/record.url?scp=0020043712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020043712&partnerID=8YFLogxK

M3 - Article

C2 - 7053252

AN - SCOPUS:0020043712

VL - 66

SP - 167

EP - 169

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 1

ER -